MADISON, Wis., Feb. 5, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place on February 13, 2024.
BTIG-hosted events are intended for prospective and existing BTIG clients only. To request a one-on-one meeting with management, please contact your BTIG representative with interest.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.
Investor Contact
Aman Patel, CFA
Investor Relations, ICR-Westwicke
+1 (443) 450-4191
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.69 |
Daily Change: | -0.07 -3.98 |
Daily Volume: | 841,498 |
Market Cap: | US$190.500M |
October 08, 2025 September 30, 2025 September 26, 2025 September 11, 2025 August 13, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load